BHVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BHVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biohaven's Other Current Receivables for the quarter that ended in Sep. 2024 was $5.32 Mil.
Biohaven's quarterly Other Current Receivables declined from Mar. 2024 ($8.43 Mil) to Jun. 2024 ($7.52 Mil) but then stayed the same from Jun. 2024 ($7.52 Mil) to Sep. 2024 ($5.32 Mil).
Biohaven's annual Other Current Receivables increased from Dec. 2021 ($9.91 Mil) to Dec. 2022 ($46.14 Mil) but then declined from Dec. 2022 ($46.14 Mil) to Dec. 2023 ($13.25 Mil).
The historical data trend for Biohaven's Other Current Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohaven Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Other Current Receivables | - | 9.91 | 46.14 | 13.25 |
Biohaven Quarterly Data | |||||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Current Receivables | Get a 7-Day Free Trial | 13.07 | 13.25 | 8.43 | 7.52 | 5.32 |
GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.
Thank you for viewing the detailed overview of Biohaven's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
John W Childs | director | 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199 |
Vlad Coric | director, officer: Chief Executive Officer | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Bruce Car | officer: Chief Scientific Officer | AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Irina Antonijevic | director | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Matthew Buten | officer: Chief Financial Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
George C. Clark | officer: VP, Chief Accounting Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Julia P Gregory | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Robert J Hugin | director | C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Kimberly Gentile | officer: SVP, Clinical Operations | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Kishan Mehta | director | 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019 |
Biohaven Pharmaceutical Holding Co Ltd. | 10 percent owner | 215 CHURCH STREET, NEW HAVEN CT 06510 |
From GuruFocus
By PRNewswire • 11-25-2024
By GuruFocus Research • 05-15-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 04-23-2024
By PRNewswire • 05-29-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 09-25-2024
By PRNewswire • 10-02-2024
By GuruFocus Research • 02-10-2024
By GuruFocus News • 11-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.